Shares of Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) traded down 7.4% during trading on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $14.54 and last traded at $14.6184. Approximately 5,467 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 233,699 shares. The stock had previously closed at $15.78.
The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). Terumo had a net margin of 13.83% and a return on equity of 10.44%.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on TRUMY. Nomura raised Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Zacks Research raised Terumo from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating. According to MarketBeat, the company presently has a consensus rating of “Strong Buy”.
Read Our Latest Stock Analysis on Terumo
Terumo Stock Performance
The business’s 50-day moving average price is $14.83 and its 200-day moving average price is $14.08. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a market cap of $21.56 billion, a PE ratio of 20.59 and a beta of 0.82.
About Terumo
Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services. Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.
Recommended Stories
- Five stocks we like better than Terumo
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
- Tesla’s Plan to End Cybertruck Reveals Its Real Priorities
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
